Related Experiment Video
Updated: Dec 23, 2025

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
Published on: November 22, 2024
Chemical evolution for taming the 'pathogenic kinase' PAK1
Hiroshi Maruta1, Atsushi Kittaka2
1PAK Research Center, Melbourne, Australia.
Abstract:
To celebrate the 25th anniversary of the cloning of the first mammalian p21-activated kinases (PAKs) (RAC/CDC42-activated kinases) by Ed Manser, the first international PAK symposium was held in NYC in October 2019. Among six distinct PAKs in mammals, PAK1 is the major 'pathogenic kinase', the abnormal activation of which is responsible for a wide variety of diseases and disorders including cancers, ageing processes and infectious and inflammatory diseases such as pandemic coronaviral infection. Recently, for a clinical application, a few potent (highly cell-permeable and water-soluble) PAK1 blockers have been developed from natural or synthetic PAK1 blockers (triptolide, vitamin D3 and ketorolac) via a series of 'chemical evolutions' that boost pharmacological activities >500 times.
Insights
p21-activated kinases (PAKs) are crucial in diseases like cancer and infections. New PAK1 blockers, developed through chemical evolution, show over 500x boosted activity for potential clinical use.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- The first mammalian p21-activated kinases (PAKs) were cloned 25 years ago, leading to the first international PAK symposium.
- Six distinct PAKs exist in mammals, with PAK1 identified as a major 'pathogenic kinase' involved in various diseases.
Purpose of the Study:
- To highlight the significance of PAK1 in diseases including cancers, aging, and infectious/inflammatory conditions.
- To discuss recent advancements in developing potent PAK1 blockers for clinical applications.
Main Methods:
- Review of research on PAK1's role in pathogenesis.
- Description of 'chemical evolution' strategies used to develop novel PAK1 blockers from existing compounds like triptolide, vitamin D3, and ketorolac.
Main Results:
- Abnormal activation of PAK1 is linked to numerous diseases, including cancers, aging, and pandemic coronaviral infections.
- Development of highly cell-permeable and water-soluble PAK1 blockers with over 500-fold increased pharmacological activity.
Conclusions:
- PAK1 is a critical therapeutic target for a range of diseases.
- Advanced PAK1 blockers demonstrate significant potential for clinical translation in treating various pathological conditions.
Related Concept Videos
MAPK Signaling Cascades
Amplifying Signals via Enzymatic Cascade
The JAK-STAT Signaling Pathway
cAMP-dependent Protein Kinase Pathways
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
PI3K/mTOR/AKT Signaling Pathway

